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Abstract
We measured immunosuppression at myeloma diagnosis and assessed the impact on survival in 5826 UK myeloma trial
patients. Polyclonal immunoglobulin levels were below normal in 85% of patients and above normal in only 0.4% of cases
for IgA, 0.2% for IgM and no cases for IgG. Immunoparesis had a greater impact in recent trials: median overall survival
(OS) was up to 3 years longer for patients without immunoparesis compared to the old trials, less than 1 year longer. Median
progression-free survival (PFS) was 39%, 36% and 57% longer for patients with normal IgG, IgA and IgM levels,
respectively. The depth of IgM suppression, but not the depth of IgG or IgA suppression, was prognostic for survival: the
most severely suppressed IgM tertile of patients OS was 0.9 years shorter than those in the top tertile, and 2.6 years shorter
than OS of those with normal IgM levels (p= .007). The degree of suppression of polyclonal IgM levels below normal was
associated with worse PFS (p= .0002). Infection does not appear to be the main mechanism through which immunoparesis
affects survival. We hypothesise that IgM immunoparesis impacts through a combination of being associated with more
aggressive disease and reduced immune surveillance against relapse.
Introduction
Multiple myeloma (MM) is an incurable neoplastic disorder
that arises from the proliferation of a single clone of plasma
cells in the bone marrow and accounts for over 10% of
haematological malignancies [1, 2]. An established feature
of MM is suppression of the adaptive immune system and
resultant low levels of polyclonal antibodies (immunopar-
esis) [3–8]. This T and B lymphocyte immunosuppression
increases the susceptibility to both bacterial and viral
infections, and the antibody levels have been shown to be
significantly lower in myeloma patients who experienced
serious infections [9–11]. Infection is a major cause of
morbidity and mortality in myeloma patients, particularly in
the first 3 months from diagnosis [10, 12, 13], with
immunoparesis, a contributory factor to this that we are
currently investigating in a UK trial of antibiotic prophy-
laxis (TEAMM). Less attention has been given to longer-
term outcomes and the hypotheses, that increasing depth of
immunosuppression is a result of more aggressive MM
(thus a marker of poor prognosis) and separately that
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immunosuppression renders MM more likely to progress
because of the reduced immune surveillance.
Immunoparesis and an associated increased risk of pro-
gression to active MM occurs in 20% of MGUS patients and
70% of smouldering MM [14 –17]. In active MM prevalence,
low antibodies increased from 63% in Durie-Salmon stage I
to 90% in stage III [4]. This was also found in a recent
registry-based study in 1755 consecutive myeloma patients
over 22 years to 2012, available through the Greek Myeloma
Study Group [18]. At least one isotype was suppressed in
77% versus 88% versus 94% of patients with International
Staging System-1, -2 and -3 disease, respectively. Preserva-
tion of the uninvolved immunoglobulins was found in 13% of
patients, which was associated with significantly longer
overall survival. This study did not include clinical trial
patients, but in a subset of 500 patients, there was sufficient
follow-up data to assess progression-free survival, which was
longer for patients with normal polyclonal antibody levels.
This group found immunoparesis commoner in patients with
IgA MM, while a previous study found immunoparesis
commoner in IgG MM [5]. These studies did not compare the
depths of immunoparesis for different antibody isotypes,
which may be important, given the different anatomical sites
of normal plasma cells secreting polyclonal IgM (lymph
nodes and spleen) versus IgG and IgA (bone marrow). In
addition, previous studies have not investigated the sig-
nificance of suppression of the alternate polyclonal free light
chain. Thus, there remains a need to investigate the sig-
nificance of the depth and character of immunoparesis in the
context of modern anti-myeloma therapy with detailed long-
term survival outcomes to explore the potential consequences
of increased risk of infection, reduced tumour surveillance
and association with poor prognosis of MM.
To further characterise the prevalence and severity of
immunoparesis at diagnosis and the prognostic significance
for overall survival (OS) and progression-free survival
(PFS), we have retrospectively analysed data from a large
cohort of 3247 newly diagnosed MM patients enroled in the
Myeloma IX and Myeloma XI clinical trials. To compare
the impact of immunoparesis on survival outcomes between
modern anti-myeloma therapy and pre-biological treatment
regimes, we also assessed the relationship between immu-
noparesis and survival in 2807 patients from the MRC
myeloma trials from 1980 to 1997, prior to the establish-
ment of novel agents and the benefit of intensive therapy.
Methods
Patients and clinical trials
Patients were enroled in either the MRC Myeloma IX (MIX)
trial (ISRCTN68454111) or the Cancer Research UK
Myeloma XI (MXI) trial (ISRCTN49407852), and henceforth
will be referred to as the ‘recent myeloma trials’. In these
multicentre, phase III trials, newly diagnosed patients were
divided between an intensive and a non-intensive pathway
based on their eligibility for the autologous stem cell trans-
plantation and assessed in relation to progression-free and
overall survival (PFS and OS). MIX randomised to receive
thalidomide versus non-thalidomide-containing therapy, tha-
lidomide could be given both as an induction and/or as a
maintenance regimen [19–22]. MXI compares lenalidomide
with thalidomide induction therapies and assesses the value of
bortezomib in poor responders. In remission, patients are
randomised to no maintenance or to receive lenalidomide, or
lenalidomide–vorinostat maintenance therapy. Data were
available for 3247 patients from MIX and MXI (up to a
randomisation date of 1 June 2013 to allow for sufficient
patient follow-up). However, only the data on 3218 out of the
3247 patients, where polyclonal IgM was recorded as part of
the central laboratory immunochemistry analysis, were
included in the patient characteristics table and multivariate
analysis. To compare these trials using current anti-myeloma
therapy to trials pre-dating novel biological agents, data were
included from 2807 patients who enroled in MRC myeloma
trials (MIV, MV, MVI and MVIII) from 1980 to 1997,
henceforth referred to as the ‘old’ myeloma trials. Treatment
allocation within these trials has been described previously
[23]. The patient characteristics table and multivariate analysis
were performed on 2608 of 2807 patients, where IgM levels
were recorded. Multicentre research ethics committees and
local ethics committees approved all the trials, and all patients
gave written informed consent.
Measures and patient classification
Serum from diagnosis was analysed centrally by protein
electrophoresis, densitometry and immunofixation for M-
protein quantification and characterisation. Serum IgG, IgA
and IgM, and kappa and lambda free light chains (sFLC)
levels were quantified by turbidimetry. Patients were char-
acterised as having one of the following multiple myelomas:
IgG, IgA, IgM, IgD, light chain only (LCO), non-secretory
(NS) or oligosecretory; with either kappa or lambda
monoclonal light chain. Patients were classified as being
below, within or above normal range (NR) for polyclonal
immunoglobulins based upon 5th–95th centile ranges of
adults aged over 45 years in the UK reported by PRU
(Protein Reference Units): IgG 6–16 g/L; IgA 0.8–4 g/L;
and IgM 0.5–2 g/L. For sFLC levels, patients were classi-
fied as being above, within or below NR (3.3–19.4 mg/L for
lambda and 5.7–26.3 mg/L for kappa) [24].
Patients were classified into two groups according to the
presence or absence of adverse cytogenetic abnormalities:
standard risk (no adverse cytogenetic abnormalities) and
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Table 1 Characterisation of patients included in the present analyses by immunoparesis of polyclonal IgM (within normal range versus below
normal range) from those enroled in MRC myeloma trials from 1980 to 1997 (old trials) compared to the MRC Myeloma IX trial (2003–2008) and
the ongoing NCRI Myeloma XI trial (2010–2016)
Old trials (MIV, MV, MVI and MVIII) Recent trials (MIX and MXI)
Factor Grouping IgM within
NR
N= 535
IgM below
NR
N= 2073
Total
N= 2608
p IgM within
NR
N= 348
IgM below
NR
N= 2870
Total
N= 3218
p
Gender Male 298 (56%) 1196 (58%) 1494
(57%)
.45 198 (58%) 1645 (59%) 1843
(59%)
.77
Female 236 (44%) 876 (42%) 1112
(43%)
144 (42%) 1148 (41%) 1292
(41%)
Age group <65 years 287 (54%) 1018 (49%) 1305
(50%)
.07 169 (49%) 1226 (43%) 1395
(44%)
.05
≥65 years 248 (46%) 1051 (51%) 1299
(50%)
179 (51%) 1632 (57%) 1811
(56%)
Pathway Intensive – – – – 210 (60%) 1627 (57%) 1837
(57%)
.21
Non-intensive – – – – 138 (40%) 1243 (43%) 1381
(43%)
M-protein type IgG 343 (64%) 1131 (55%) 1474
(56%)
.001 231 (66%) 1700 (59%) 1931
(60%)
.002
IgA 123 (23%) 580 (28%) 703 (27%) 60 (17%) 708 (25%) 768 (24%)
IgD 4 (1%) 36 (2%) 40 (2%) 4 (1%) 51 (2%) 55 (2%)
IgE 1 (<1) 1 (<1) 2 (<1%) – – –
Light chain only 55 (10%) 296 (14%) 351 (13%) 43 (12%) 370 (13%) 413 (13%)
Non-secretory 9 (2%) 29 (1%) 38 (1%) 7 (2%) 17 (1%) 24 (1%)
Oligosecretory – – – 3 (1%) 24 (1%) 27 (1%)
% BMPCs <20 152 (40%) 331 (21%) 483 (24%) <.0001 189 (61%) 774 (29%) 963 (32%) <.0001
20–50 156 (41%) 724 (45%) 880 (44%) 99 (32%) 1182 (45%) 1281
(43%)
>50 76 (20%) 559 (35%) 635 (32%) 23 (7%) 699 (26%) 722 (24%)
Sb2m (mg/l) ≤4 208 (40%) 460 (23%) 668 (26%) <.0001 235 (68%) 1317 (46%) 1552
(48%)
<.0001
4–8 195 (37%) 807 (40%) 1002
(39%)
89 (26%) 1069 (37%) 1158
(36%)
>8 117 (23%) 765 (38%) 822 (35%) 23 (6%) 480 (17%) 503 (16%)
Albumin (g/l) <30 79 (22%) 458 (29%) 537 (27%) .001 55 (17%) 559 (20%) 614 (20%) .008
30–35 106 (30%) 535 (33%) 641 (33%) 81 (24%) 846 (30%) 927 (30%)
>35 174 (48%) 612 (38%) 786 (40%) 195 (59%) 1397 (50%) 1592
(51%)
eGFR ml/min <30 89 (17%) 453 (22%) 542 (21%) .0003 19 (6%) 287 (10%) 306 (10%) .008
30–60 230 (43%) 961 (46%) 1191
(46%)
116 (34%) 995 (36%) 1111
(35%)
>60 215 (40%) 654 (32%) 869 (33%) 207 (60%) 1502 (54%) 1709
(55%)
ISS I 81 (17%) 146 (7%) 227 (9%) <.0001 134 (41%) 608 (22%) 742 (24%) <.0001
II 169 (36%) 617 (32%) 786 (33%) 128 (39%) 1086 (40%) 1214
(40%)
III 214 (46%) 1189 (61%) 1403
(58%)
67 (20%) 1024 (38%) 1091
(36%)
LDH IU/L <273 – – – 92 (36%) 892 (42%) 984 (41%) .07
≥273 – – – 163 (64%) 1224 (58%) 1387
(59%)
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high risk (one or more adverse cytogenetic abnormalities).
Adverse cytogenetic abnormalities were defined as gain
(1q), t(4;14), t(14;16), t(14;20) or del(17p) [22, 25].
Statistical analyses
Immunoparesis at diagnosis was assessed for patients in
MIX and MXI trials. Mann–Whitney U-tests and
Kruskal–Wallis tests were used for comparisons between
M-protein groups and kappa and lambda myelomas, as
appropriate. Spearman’s rank correlations were performed
to evaluate the relationships between M-protein and poly-
clonal immunoglobulins, and sFLC. Data were analysed
using IBM SPSS statistics version 21.
Patient characteristics are presented for old and recent
myeloma trials by polyclonal IgM (within NR, below NR).
Differences in patient characteristics were investigated using
the Pearson’s χ2-test with continuity adjustment used
wherever appropriate. Survival curves were constructed
using the method of Kaplan and Meier, and the log-rank test
was used to assess the differences between the groups, in the
old myeloma trials and recent myeloma trials [26, 27]. OS
was defined as ‘date of entry to the trial’ to ‘date of death’ or
censored at ‘last alive date’. PFS was defined as time from
date of entry to progression or death, or censored at date last
known to be alive and progression free. Progression was
defined as relapse from complete response, if one was
achieved or documented progressive disease [28]. Survival
outcomes were analysed between patients who were below
or within the NR for polyclonal immunoglobulins and FLCs,
and assessed based on the degree of immunoparesis. Degree
of immunoparesis was obtained by splitting the patients who
were below the NR into three groups for IgG, IgA and IgM
individually. Cox regression was performed to determine
whether polyclonal IgM was an independent predictor of OS
and PFS after adjusting for Sβ2M, BMPCs and ISS in the
old trials, with the addition of LDH and genetic risk in the
recent trials [29]. Survival analysis and Cox regression were
performed using SAS statistical software (SAS Institute,
SAS Circle, Cary, NC, USA).
Results
Patient characteristics
The study included 2608 patients older MRC trials (21%
with polyclonal IgM within NR and 79% with polyclonal
IgM below NR) all receiving conventional therapy as
described previously, Table 1 [23]; and 3218 patients from
recent trials (11% with polyclonal IgM within NR and 89%
with polyclonal IgM below NR). The proportion of patients
aged ≥65 years increased from 50% in the old trials to 56%
in recent trials, reflecting an increase in patients ≥65 years
receiving intensive therapy. Twenty-four per cent of
patients were ISS stage I in recent trials compared to 9% in
older trials reflecting improvements in diagnosis.
Comparison of factors between groups with IgM within
the NR and IgM below the NR in the older trials and recent
trials demonstrated an increase in BMPCs and Sβ2M in IgM
below NR groups compared to the within NR group,
p < .0001, Table 1. Albumin was higher, where IgM was
within the NR in both old and recent trials (p= .001 and p
= .008, respectively). LDH recorded in the recent trials did
not significantly differ between groups (p= .07). Patients
with lower IgM were more likely to have adverse cytoge-
netic abnormalities present compared to those with IgM
within NR (24% versus 12%, p= < .0001).
Characterisation of immunoparesis
Figure 1 illustrates the distribution of polyclonal IgG, IgA
and IgM levels in patients without an IgG, IgA or IgM M-
protein, respectively. IgM levels were below the NR in 89%
of patients compared to 80% of patients for IgG and IgA
levels. Median polyclonal levels (IQR) for IgG, IgA and
IgM were 3.9 (2.7–5.6), 0.3 (0.2–0.6) and 0.2 (0.1–0.3) g/L,
respectively. These values represent a reduction below the
median value of the NR of 65% for IgG, 87% for IgA and
84% for IgM. No patient without an IgG M-protein had an
IgG level above the NR of 16 g/L. A small proportion of
patients presented with IgA (0.4%) and IgM levels (0.2%)
Table 1 (continued)
Old trials (MIV, MV, MVI and MVIII) Recent trials (MIX and MXI)
Factor Grouping IgM within
NR
N= 535
IgM below
NR
N= 2073
Total
N= 2608
p IgM within
NR
N= 348
IgM below
NR
N= 2870
Total
N= 3218
p
Genetic risk Standard risk – – – 115 (33%) 798 (28%) 913 (28%) <.0001a
High risk – – – 43 (12%) 694 (24%) 737 (23%)
Unknown 190 (55%) 1378 (48%) 1568
(49%)
aTest is based on those with a result only
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above the NR; median (IQR) concentrations in these
patients were 4.4 g/L (4.1–4.8 g/L) and 2.48 g/L (2.1–3.2 g/
L), respectively. Individuals who were above the NR for
IgA included five IgG patients, five LCO patients and one
IgM patient. Patients who were above the NR for IgM
comprised six IgA and two IgG patients.
Immunoparesis by myeloma M-protein type
Polyclonal immunoglobulin levels based on myeloma M-
protein type are presented in Fig. 2. Group differences in
immunoparesis were evaluated between the three main
patient M-protein groups (IgG, IgA and LCO) who together
made up 95% of all patients. IgA patients had the most
profound immunoparesis, followed by IgG and then LCO
patients, but differences between the M-protein types,
although statistically significant, were not substantial
(Fig. 2). Similarly, lambda patients demonstrated sig-
nificantly but not substantially, lower polyclonal immu-
noglobulins across IgG, IgA and LCO patient groups
(Supplementary Figure S1). Statistics were not performed
for the remaining patient groups (IgD, IgM, NS and oli-
gosecretory myeloma) due to small sample sizes; however,
IgD patients had the lowest median polyclonal levels of all
M-protein groups. This may be due to the high prevalence
of lambda light chain type in IgD myeloma.
Inverse relationship between M-protein level and
polyclonal immunoglobulin levels
Higher M-protein levels were associated with significantly
lower levels of polyclonal immunoglobulins. The strongest
Fig. 1 Levels of polyclonal immunoglobulin in MIX and MXI clinical
trials. Data are presented for levels of polyclonal IgG (a, n= 1302),
IgA (b, n= 2469) and IgM (c, n= 3226) at disease presentation in all
myeloma patients without an IgG, IgA or IgM M-protein, respectively.
For patients above normal ranges (NR), number of patients, percentage
of patients and 95% confidence interval (CI) ranges for the percentage
of patients are shown
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negative correlation was seen for IgA M-protein and poly-
clonal IgG (rs= –.414). The amount of IgA M-protein also
negatively correlated with the level of polyclonal IgM,
rs= –.253. In patients with IgG myeloma, negative rela-
tionships were also found between M-protein level and
polyclonal IgA (rs= –.271) and IgM levels (rs= –.254).
These relationships are illustrated in Supplementary Fig-
ure S2 (p < 0.001 for all correlations).
Inverse relationship between M-protein level and
polyclonal free light chain levels
The level of polyclonal sFLC (uninvolved immunoglobulin)
was inversely correlated with whole IgG or IgA M-protein
level (Supplementary Figure S3, p < 0.05 for all correla-
tions). These plots of polyclonal sFLCs versus M-protein
illustrate that Freelite did not identify polyclonal kappa
sFLC levels between 2.5 and 5.5 mg/L and polyclonal
lambda patients between 1.5 and 3.5 mg/L. To overcome
this problem, we analysed kappa and lambda sFLC levels in
a sub-cohort of IgG and IgA patients using monoclonal anti-
free light chain reagents on a Luminex platform [30], which
enabled a more sensitive assessment of the distribution of
polyclonal sFLC levels without gaps in measurement
(Supplementary Figure S4). These produced correlations of
the same direction and strength compared to Freelite, with
the exception of IgA lambda patients, where a stronger
relationship was observed using Luminex data (rs= –.406,
p= 0.0001) compared to Freelite (rs= –.126, p= 0.03). As
the assessment of polyclonal sFLC was more precise with
the Luminex assay for measurement below the NR, we used
the platform to later assess the relationship between sFLC
immunoparesis and survival outcomes.
Survival outcomes by M-protein type
Survival data were available for 2587 patients from the
old trials and 3109 from recent trials. Patients with IgG
myeloma survived the longest in the old trials (median
2.52 years), followed by IgA myelomas (median 2.33
years) with LC-only myeloma patients doing worst
(median 1.94 years, p < .0001, Supplementary Table 1).
IgG patients continue to survive longest in recent trials
and median OS has increased from 2.52 years in the old
trials to 4.75 years. Light chain-only myeloma patients
also benefited from increased OS (median 4.32 years in
recent trials compared to 1.94 years in the old trials) and
PFS (median 1.92 years in recent trials compared to 1.46
years in the older trials).
Immunoparesis is associated with poorer survival
outcomes
Patients from the recent trials survived longer than patients
from the old clinical trials, median OS 4.53 years (95% CI
= 4.32–4.84) and 2.33 years (95% CI= 2.23–2.46),
Fig. 2 Levels of polyclonal
immunoglobulins by the three
main patient M-protein
subgroups in MIX and MXI.
Statistics were performed for the
three main patient groups with
sufficient sample size (IgG, IgA
and LCO). Significant
differences between groups are
indicated, ***p < 0.001. Dotted
lines indicate the lower limit of
the normal range of serum
polyclonal immunoglobulin
concentration: 6 g/L IgG, 0.8 g/L
IgA and 0.5 g/L IgM
J. L. J. Heaney et al.
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respectively, despite a greater proportion of patients being
older in the more recent trials. In both old and recent
myeloma clinical trials, patients with immunoparesis at
diagnosis had significantly poorer PFS and OS compared
with patients for whom polyclonal immunoglobulin levels
were within the NR (p < 0.01 for all comparisons, Supple-
mentary Table 2). The association of immunoparesis with
poor survival was stronger in recent than old trials. In the
old trials, individuals with normal levels of polyclonal IgG
had a median OS that was 19% longer than the OS of
individuals with low IgG; in the recent trials, this OS benefit
for individuals with normal levels of polyclonal IgG at
diagnosis was 80% longer than in those with immunopar-
esis. For polyclonal IgA levels, OS was 30% and 39%
longer and for IgM 29% and 50% longer in old and recent
trials, respectively.
In the recent trials, median OS (95% CI), in years, for
normal (19% of patients) versus low (81% of patients)
polyclonal IgG was 6.93 (CI 4.89–7.33) and 3.84
(3.44–4.37), respectively; for normal (19% of patients)
versus low (81% of patients) polyclonal IgA levels was
6.15 (5.21–7.33) and 4.42 (4.15–4.82), respectively; for
normal (11% of patients) versus low (89% of patients)
polyclonal IgM levels was 6.59 (5.29–8.08) and 4.37
(4.14–4.64), respectively (all p < 0.0003; Supplementary
Table 2). In the recent trials, median PFS, in years (95%
CI), for normal versus low polyclonal IgG levels was 2.41
(1.96–3.12) and 1.73 (1.62–1.86), respectively; for nor-
mal versus low polyclonal IgA levels was 2.49
(2.03–2.79) and 1.83 (1.73–1.93), respectively; for nor-
mal versus low polyclonal IgM levels was 2.83
(2.28–3.17) and 1.80 (1.72–1.89), respectively (all
p < 0.0001; Supplementary Table 2).
Immunoparesis of the uninvolved sFLC (either kappa or
lambda) did not impact upon OS or PFS; notably over two-
thirds of patients had polyclonal sFLC levels in the NR,
which in part reflects the high prevalence of reduced glo-
merular filtration in myeloma, itself an adverse factor for
survival (Supplementary Table 2).
The depth of IgM suppression, but not the depth of
IgG or IgA suppression, is a prognostic factor for
survival outcomes
In the recent MIX and MXI trials, median OS was 6.59
years in the 342 patients with normal polyclonal IgM levels
at diagnosis and 4.37 years in the 2855 patients with IgM
levels below the NR at diagnosis. Dividing these 2855
Fig. 3 Survival outcomes in relation to degree of IgM immunoparesis.
Overall survival by degree of immunoparesis of polyclonal IgM levels
for old trials (a) and recent MIX and MXI trials (b). Progression-free
survival by degree of immunoparesis of polyclonal IgM levels pre-
sented for old trials (c) and recent MIX and MXI trials (d). Patients
below the normal range for polyclonal IgM (<0.5 g/L) were divided
into three tertiles based upon degree of suppression: slightly below
normal >0.2 to <0.5 g/L; moderately below normal >0.1 to ≤0.2 g/L;
severely below normal <0.1 g/L
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patients into tertiles, median OS in the lowest IgM tertile
group was 4.02 years compared to 4.26 years in the middle
group and 4.92 years in the tertile with the least severe
immunoparesis (p= 0.007; Table 2 and Fig. 3). Examining
the depth of immunoparesis by tertiles for polyclonal IgG
and IgA levels at diagnosis showed no significant difference
at p= 0.98 and 0.65, respectively. The same was found in
the old trials, where the greater the depth of IgM immu-
noparesis, the shorter the median OS, whereas the depth of
IgG or IgA immunoparesis was not associated with altered
OS (Table 2).
In these recent trials, median PFS was 2.83 years in the
342 patients with normal polyclonal IgM levels at diagnosis
and 1.80 years in the 2855 patients with IgM levels below
the NR. Again, when dividing these 2855 patients into
tertiles, median PFS in the lowest IgM tertile group was
1.71 years compared to 1.79 years in the middle group and
1.97 years in the tertile with the least severe immunoparesis
(p= 0.0002; Table 2 and Fig. 3). Examining the depth of
immunoparesis by tertiles for polyclonal IgG and IgA levels
at diagnosis showed no significant difference for PFS
(p= 0.23 and 0.54, respectively). The same was found in
the old trials, where the greater the depth of IgM immu-
noparesis, the shorter the median PFS was while depth of
IgG or IgA immunoparesis was not associated with a dif-
ference in PFS (Table 2).
It is evident in the Kaplan–Meier curves in Fig. 3 that the
survival advantages associated with higher levels of IgM
only become apparent after the first year. Analysis of sur-
vival data up to 6 months has shown no difference in early
deaths between immunoparesis groups. OS was 92% at
6 months for patients with IgM within the NR and 91% in
patients with IgM below NR, log rank p= 0.65. PFS was
89% within NR and 87% below NR, p= 0.21.
Cox regression models were fitted to assess the indepen-
dent effects of polyclonal IgM on OS and PFS after adjusting
for known prognostic factors (age greater or less than 65
years, Sβ2M, BMPCs, ISS and sex) in the older trials with
the addition of genetic risk for recent trials, Table 3. These
models confirmed polyclonal IgM as an independent prog-
nostic factor of PFS in the old trials (HR= 0.84 (95% CI=
0.73–0.98), p= 0.02). Polyclonal IgM was confirmed to be
an independent prognostic factor of OS and PFS in the recent
trials HR= 0.64 (95% CI= 0.42–0.97, p= 0.04) and 0.62
(95% CI= 0.46–0.83, p= 0.002), respectively.
Polyclonal IgM suppression was shown to be an inde-
pendent prognostic factor for both OS and PFS when con-
trolling for SB2m, age, BMPCs, ISS, sex and genetic risk in
recent trials (p= 0.04 and p= 0.002, respectively, Table 3).
For each point increase in polyclonal IgM, the hazard of
death decreased by an estimated 36% and progression or
death by an estimated 38%. Within the old trials, IgM
immunoparesis was found to be prognostic of PFS inde-
pendent of Sβ2M, age, BMPCs, ISS and sex, p= 0.02.
Discussion
This study provides in-depth analysis of immunoparesis in
newly diagnosed MM patients enroled into UK clinical
Table 3 Cox regression table to predict overall survival (OS) and progression-free survival (PFS) from those enroled in MRC myeloma trials from
1980 to 1997 (old trials) compared to the MRC Myeloma IX trial (2003–2008) and the ongoing NCRI Myeloma XI trial (2010–2016)
Old trials (MIV, MV, MVI and MVIII) Recent trials (MIX and MXI)
Factor Grouping N HR (95% CI) p Factor Grouping N HR (95% CI) p
OS
SB2M group ≤4, 4–8, >8 1926 1.32 (1.19–1.46) <.0001 SB2M group ≤4, 4–8, >8 145 1.04 (1.02, 1.06) .0002
Age group <65 yrs, ≥65 yrs 1.25 (1.14–1.38) <.0001 Age group <65 yrs, ≥65 yrs 1.83 (1.55, 2.17) <.0001
% BMPCs <20, 20–50, >50 1.17 (1.09–1.25) <.0001 % BMPCs <20, 20–50, >50 1.10 (0.98, 1.23) .11
ISS I, II, III 1.18 (1.05–1.32) .005 ISS I, II, III 1.32 (1.15, 1.52) <.0001
Polyclonal IgM Continuous 0.89 (0.77–1.03) .12 Polyclonal IgM Continuous 0.64 (0.42, 0.97) .04
Sex Male, female 0.91 (0.83–1.00) .06 Sex Male, female 1.04 (0.88, 1.22) .68
Genetic risk SR, HR 1.65 (1.40, 1.95) <.0001
PFS
SB2M group ≤4, 4–8, >8 1921 1.21 (1.09–1.33) .0002 SB2M group ≤4, 4–8, >8 1415 1.03 (1.01, 1.05) .0002
Age group <65 yrs, ≥65 yrs 1.13 (1.03–1.24) .01 Age group <65 yrs, ≥65 yrs 1.75 (1.54, 1.99) < .0001
% BMPCs <20, 20–50, >50 1.23 (1.15–1.31) <.0001 % BMPCs <20, 20–50, >50 1.05 (0.96, 1.28) .33
ISS I, II, III 1.19 (1.06–1.32) .003 ISS I, II, III 1.16 (1.15, 1.51) .005
Polyclonal IgM Continuous 0.84 (0.73–0.98) .02 Polyclonal IgM Continuous 0.62 (0.46, 0.83) .002
Sex Male, female 0.91 (0.83–0.99) .04 Sex Male, female 1.13 (0.99, 1.28) .07
Genetic risk SR, HR 1.39 (1.22, 1.58) <.0001
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trials. To our knowledge, this is the first study of this nature
in a large cohort of patients enroled in national clinical
trials. Findings exposed a notably high incidence of
immunoparesis at diagnosis, where, in 80% of patients,
polyclonal IgG and IgA immunoglobulin levels were below
the NR, and for 89% of patients, polyclonal IgM levels were
below the NR. The degree of immunoparesis was also
severe, with median polyclonal values presenting sub-
stantially below the lower limit of the NRs. The distribution
of polyclonal immunoglobulin levels observed in the pre-
sent analysis also conveys a simple, yet important, clinical
message in determining the diagnosis of MM versus other
monoclonal gammopathies. If polyclonal immunoglobulins
are above the NR, then the patient almost certainly does not
have MM. This is supported by none of the 1302 patients
without an IgG M-protein being above the NR for poly-
clonal IgG, and only 8/3226 (0.2%) of patients exhibiting
polyclonal IgM levels above NR.
The impact of intact M-protein type on immunoparesis
has yielded conflicting findings in previous studies. One
study of 940 patients found no significant differences
between classes of M-protein [4], whereas another previous
investigation of 1027 patients found uninvolved immu-
noglobulins were reduced in a higher proportion of IgA
compared with IgG M-protein patients [2]. We have found
the degree of immunoparesis was greatest in patients with
IgD and IgA M-protein heavy chain types and with lambda
light chain type, but these differences between M-protein
types were not large. Similarly, there was a significant but
not close association between M-protein levels and degree
of immunoparesis. Importantly, LCO patients had severe
immunoparesis, indicating that the mechanism of immu-
noparesis is not dependent on Fc regions of M-proteins.
In the present study, the presence of immunoparesis
alone was associated with a negative effect on patient sur-
vival and disease control: for each point increase in IgM
immunoglobulin levels decreased the risk of death by up to
36%. This is consistent with a previous study, which found
preservation of polyclonal immunoglobulins was associated
with improved survival in 1755 patients and longer PFS in a
smaller sub-cohort of 500 patients [18]. Although, in a more
recent Danish multiple myeloma registry study, immuno-
paresis was associated with shorter PFS, while the shorter
OS was not significant in multivariable analysis [31]. The
present investigation confirms and extends these findings to
a larger population of patients in the context of national
clinical trials.
We compared the impact of immunoparesis on survival
outcomes in different eras of therapy through assessment of
both historical (2608 patients) and recent UK clinical trials
(3218 patients). Despite a greater proportion of patients
being aged ≥65 years in the more recent MIX and MXI
trials, adding predominantly thalidomide or lenalidomide
with dexamethasone, patients lived twice as long as the
patients from the old trials. This re-confirms the superior
efficacy of current anti-myeloma therapies. Importantly, this
study highlights preservation of polyclonal immunoglobulin
levels of G, A or M class at diagnosis, as a key prognostic
factor for OS and PFS in older trials irrespective of age <65
yrs/≥ 65 yrs and with an even more profound effect in recent
trials employing modern therapy in both intensive and non-
intensive pathways. From old to recent trials, survival has
doubled for all patients but the differences in median overall
survival times between patients within or below the NR
were more pronounced for the new trials (up to 3 years)
compared to the old trials (less than 1 year). For patients
with normal versus reduced IgM levels, median OS was
longer by 29% in old trials and 51% in new trials. Similarly,
PFS was longer by 25% in old and 57% in recent trials. This
reveals that improved survival from modern therapies has
been greatest in patients without severe immunoparesis and
that the mechanism of immunoparesis may be an important
new therapeutic target.
Over two-thirds of patients had normal levels of poly-
clonal free light chains and this was not associated with
better survival probably because the normal levels were
more often the result of reduced glomerular filtration rather
than preservation of secretion; 45% of patients had an eGFR
<60 mls/min. In recent trials comparing patients with nor-
mal polyclonal levels with patients with levels below the
NR, median OS and median PFS were significantly longer
for patients with normal IgG, IgA or IgM levels. However,
only a small proportion of patients had normal immu-
noglobulin levels (≤20%) and so it was important to see the
effect on survival of depth of suppression of polyclonal
immunoglobulin levels below the NR. Depth of suppression
of polyclonal IgG or IgA levels below the NR was not
associated with worse PFS or OS. In contrast, the degree of
suppression of polyclonal IgM levels below the NR was
significantly associated with survival. In recent trials, the
most severely suppressed tertile of patients OS was 0.9
years (18%) shorter than those in the top tertile and 2.57
years (39%) shorter than OS of those with IgM levels within
the NR. Similarly, the degree of suppression of polyclonal
IgM levels below the NR was significantly associated with
worse PFS. The most severely suppressed tertile of patients
PFS was 0.26 years (13%) shorter than those in the top
tertile and 1.12 years (40%) shorter than PFS of those with
IgM levels within the NR.
IgM antibodies are the first class of antibodies produced
following antigen exposure, offering early protection
against microbial infection and are derived predominantly
from secondary lymphoid tissues, not the bone marrow
[32]. Consequently, a reduced IgM level in newly diag-
nosed MM patients has implications for primary antibody
response, vaccination efficacy and risk of infection.
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However, reduced secretion of polyclonal IgM from plasma
cells distant from bone marrow also highlights the question
of mechanism of immunosuppression and the hypothesis
that it might be associated with aggressive MM and reduced
immune surveillance of MM.
Infection reaps the greatest toll in mortality in the early
months from diagnosis during active disease and we are
currently investigating the complexity of that innate and
specific immunosuppression in the TEAMM trial that has
compared prophylactic levofloxacin antibiotic prophylaxis
with placebo. It is clear from the survival curves in Fig. 3
that IgM immunoparesis had little effect on survival during
this period while it had a profound effect on overall survival
in both old and modern trials. The effect on PFS, in which
infection is unlikely to play a major part, is even more
interesting. The level of IgM immunoparesis may reflect
disease activity/severity and therefore the depth of IgM
suppression may be a proxy marker of inherent malignancy
and possible resistance to therapy. The mediating factors
between low IgM levels and risk of death/disease progres-
sion require further investigation and future studies may
seek to identify the underlying mechanisms between
immunoparesis and patient outcomes. A recent study found
recovery of polyclonal immunoglobulins 1 year after auto-
logous stem cell transplantation predicts progression-free
and overall survival [33]. Subsequent studies should con-
sider the relative importance of immunoparesis at diagnosis
versus post therapy in relation to long-term outcomes.
Conclusion
The results from this large data set of newly diagnosed MM
patients provide a comprehensive up-to-date characterisa-
tion of immunoparesis at diagnosis and demonstrate the
strong prognostic significance for both progression-free
survival and overall survival in historical trials and even
more profoundly in present-day clinical trials featuring
modern anti-myeloma therapy. In contrast to polyclonal IgG
and IgA, it is not simply the presence of immunoparesis but
for polyclonal IgM also its severity that predicts patient
survival. Immunoparesis is generally thought to reduce
survival by increased infection rates but this does not seem
to be the predominant mechanism. There is little impact of
immunoparesis in the first 6 months from diagnosis the time
at which infection is most common. Further immunoparesis
profoundly reduces PFS that in itself is little dependent
upon infection rates. We hypothesise that IgM immuno-
paresis impacts survival through a combination of being
associated with more aggressive disease and reduced
immune surveillance. This impact is much greater in recent
trials revealing that improved survival from modern thera-
pies has been greatest in patients without severe
immunoparesis and that the mechanism of immunoparesis
may be an important new therapeutic target.
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